Wall Street analysts expect that Mylan NV (NASDAQ:MYL) will announce $2.84 billion in sales for the current quarter, according to Zacks. Five analysts have provided estimates for Mylan’s earnings, with the lowest sales estimate coming in at $2.75 billion and the highest estimate coming in at $2.90 billion. Mylan posted sales of $2.81 billion during the same quarter last year, which suggests a positive year-over-year growth rate of 1.1%. The firm is expected to report its next quarterly earnings results on Wednesday, August 14th.
On average, analysts expect that Mylan will report full year sales of $11.69 billion for the current fiscal year, with estimates ranging from $11.50 billion to $11.87 billion. For the next fiscal year, analysts expect that the company will post sales of $12.17 billion, with estimates ranging from $11.78 billion to $12.79 billion. Zacks Investment Research’s sales averages are an average based on a survey of analysts that follow Mylan.
Mylan (NASDAQ:MYL) last issued its earnings results on Tuesday, May 7th. The company reported $0.82 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $0.79 by $0.03. The firm had revenue of $2.50 billion during the quarter, compared to the consensus estimate of $2.70 billion. Mylan had a return on equity of 18.96% and a net margin of 2.14%. The business’s quarterly revenue was down 7.0% on a year-over-year basis. During the same quarter in the previous year, the firm earned $0.96 earnings per share.
In related news, insider Paul Campbell sold 11,533 shares of the company’s stock in a transaction that occurred on Monday, March 4th. The stock was sold at an average price of $27.50, for a total value of $317,157.50. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Corporate insiders own 0.81% of the company’s stock.
Hedge funds have recently made changes to their positions in the stock. Global Retirement Partners LLC lifted its stake in Mylan by 107.1% in the first quarter. Global Retirement Partners LLC now owns 967 shares of the company’s stock valued at $27,000 after buying an additional 500 shares during the period. Pinnacle Bank lifted its stake in Mylan by 66.4% in the first quarter. Pinnacle Bank now owns 1,060 shares of the company’s stock valued at $30,000 after buying an additional 423 shares during the period. Cresset Asset Management LLC acquired a new position in Mylan in the first quarter valued at approximately $41,000. Mascoma Wealth Management LLC acquired a new position in Mylan in the first quarter valued at approximately $47,000. Finally, Kinneret Advisory LLC acquired a new position in Mylan in the fourth quarter valued at approximately $71,000. Institutional investors and hedge funds own 82.73% of the company’s stock.
NASDAQ MYL traded down $0.48 during trading on Friday, hitting $19.17. 6,231,318 shares of the company’s stock were exchanged, compared to its average volume of 6,253,940. The company has a current ratio of 1.51, a quick ratio of 0.85 and a debt-to-equity ratio of 1.20. The company has a market cap of $10.14 billion, a price-to-earnings ratio of 4.19, a PEG ratio of 1.02 and a beta of 1.44. Mylan has a fifty-two week low of $18.93 and a fifty-two week high of $42.50.
Mylan N.V., together with its subsidiaries, develops, licenses, manufactures, markets, and distributes generic, branded-generic, brand-name, and over-the-counter (OTC) pharmaceutical products in North America, Europe, and internationally. It offers active pharmaceutical ingredients and finished dosage forms; and antiretroviral medicines to treat HIV/AIDS.
Read More: What is systematic risk?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Mylan Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mylan and related companies with MarketBeat.com's FREE daily email newsletter.